Simultaneous targeting of multiple etiological using a nanosized strategy for psoriasis management

Area of Science:

• Dermatology and Nanomedicine: Focus on advanced therapeutic strategies for skin diseases.

Background:

• Psoriasis is a chronic inflammatory skin condition characterized by immune system dysregulation, abnormal cell growth, and inflammation.
• Current psoriasis treatments face limitations, necessitating novel approaches that target multiple disease pathways simultaneously.

Purpose of the Study:

• To develop and evaluate a novel nanoparticle formulation (LR@HBn) for targeted topical delivery in psoriasis treatment.
• To assess the efficacy of LR@HBn in modulating key signaling pathways (PPARγ, EGFR, NF-κB) involved in psoriasis pathogenesis.

Main Methods:

• Development and optimization of bilirubin-conjugated hyaluronic acid-assembled nanoparticles co-loaded with lapatinib and rosiglitazone (LR@HBn).
• Evaluation of nanoparticle characteristics including size, zeta potential, drug loading, and ROS responsiveness.
• Assessment of skin penetration, retention, and therapeutic efficacy in vitro and in vivo models.
• Encapsulation of LR@HBn into a carboxymethyl chitosan gel for topical administration (LR@HBn-G).

Main Results:

• Optimized LR@HBn nanoparticles exhibited favorable physicochemical properties (size ~79 nm, negative zeta potential, >80% entrapment efficiency).
• LR@HBn demonstrated significant ROS-scavenging ability and targeted drug delivery to lesion sites.
• In vitro and in vivo studies confirmed LR@HBn's potent antioxidative, anti-inflammatory, and anti-proliferative effects, leading to psoriasis symptom attenuation and recurrence prevention.

Conclusions:

• LR@HBn nanoparticles represent a promising topical therapeutic strategy for psoriasis, effectively addressing multiple pathological aspects of the disease.
• The developed nanoparticle-gel formulation offers enhanced skin penetration and retention, paving the way for advanced psoriasis management.